Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa.

Background: Many women affected by hidradenitis suppurativa (HS) are of childbearing age. To date, the literature is limited on pregnancy-related outcomes for women with HS.
Objective: To investigate maternal and obstetric outcomes and treatment utilization among women with HS.
Methods: This retrospective analysis used the IBM MarketScan Commercial Claims Database. Pregnant women with HS (n = 998) and 5:1 age-matched pregnant women without HS (n = 5065) were identified and information on claims related to diagnoses, procedures, and medications were analyzed.
Results: Compared to women without HS, pregnant women with HS had significantly lower odds of having a live birth (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.39-0.51) and significantly higher odds of having elective terminations (OR, 2.51; 95% CI, 2.13-2.96), gestational hypertension (OR, 1.44; 95% CI, 1.12-1.84), and cesarean deliveries (OR, 1.28; 95% CI, 1.06-1.55), and of receiving HS designated treatment during pregnancy (OR, 4.41; 95% CI, 3.56-5.46).
Limitations: Retrospective and convenience sampling and absence of clinical information to correlate HS severity and outcomes.
Conclusion: Pregnant women with HS have an increased probability of select complicated maternal and obstetric outcomes. Women planning for pregnancy or who are currently pregnant may benefit from coordinated care by dermatologists and obstetric providers.
Competing Interests: Conflicts of interest Dr Kirby is a consultant and speaker for AbbVie, receives honoraria for participating on an Advisory Board for AbbVie, and receives honoraria as a consultant for ChemoCentryx, Incyte, Janssen, Novartis, and UCB Pharma. Authors Sakya and Maczuga and Dr Hallan certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, participation in speakers' bureaus, membership, employment, consultancies, stock ownership, other equity interest, or expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
(Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)